Abstract: In the past, Pneumocystis jiroveci (formerly P. carinii) belonged to the Protozoa group, but the studies on structure of the cell wall and nucleotide sequence resulted in the reclassification of this organism in the kingdom Fungi. P. jiroveci is an opportunistic pathogen, responsible for pneumocystis pneumonia with frequent complications of immunocompromised patients. Delayed initiation of appropriate therapy increases the risk of death in immunocompromised patient. The aim of this work was to determine the prevalence of P. jiroveci from patients suspected of having respiratory tract infections in southwestern Slovakia over a 10-year period. Due to the increasing number of immunosuppressed persons, the diagnostic of P. jiroveci in patients with pulmonary complications is essential to improve recovery onsets. Effective diagnosis is currently based on microscopic examination and detection of parasite DNA by polymerase chain reaction (PCR) in bronchoalveolar lavage (BAL) and induced sputum. In total, 386 clinical samples originated from patients suspected of pneumocystis infection were tested within ten years. Requirements for diagnosis of the pathogen were growing during the period. Three hundred and sixteen BALs, 59 induced sputa, 10 lung biopsies and 1 liquor were subjected to the detection of P. jiroveci. P. jiroveci DNA was detected in 30 patients using PCR, but cysts of microorganism were present only in 4 cases by microscopy. The pathogen was confirmed in 24 BALs and 6 sputa samples. The presence of P. jiroveci has been demonstrated mainly in immunocompromised individuals with cancer (20), but also in patients with pneumonia (6+1 HIV), with unspecified parasitic diseases (1+1HIV) and with systemic lupus erythematosus (1).
Introduction
Pneumocystis jiroveci is a single-celled organism, responsible for pneumocystis pneumonia (PcP) in immunocompromised patients, i.e., patients with AIDS, people with autoimmune disorders, malignancy patients, transplant recipients, and patients receiving immunosuppressive therapy. P. jiroveci has the morphological characteristics typical of protozoa and therefore was considered as such. Now, it is classified as a fungus because its cell wall composition and nucleotide sequences of small subunit ribosomal RNA are more similar to those of fungi. Although much evidence suggests that P. jiroveci is a fungus, it is not susceptible to antifungal drugs such as amphotericin B because of the lack of ergosterol, which is the major sterol of fungi (Jang-Jih & Chao-Hung 2008) .
Pneumocystis jiroveci occurs mostly in the lungs, where it is forming the two main stages in the pneumocystis life cycle. Very irregular trophic forms (2-8 µm in diameter) display cytoplasmic projections known as filopodia, which allow them to attach closely to type I pneumocytes and multiply within. Under certain unknown circumstances, vegetative forms further thicken at a thick-walled mature cyst (4-7 µm in diameter) with a smooth surface and morphology resembling a deformed ball. Reproduction at the cellular level can be sexual and asexual. In the case of asexual binary division, mononuclear thin-walled trophic forms (ameboid in shape) are attached to the epithelial alveolar cell. Trophozoites and cysts are present in sexual reproduction. Conjugation of trophic forms would evolve into thin-walled round early sporocyte. Following meiotic division leads to the formation of intermediate sporocyte.
An additional mitotic replication leads to a thick-walled late sporocyte with 8 spores. Finally, spores leave the cyst to give rise free haploid trophic forms (AliouatDenis et al. 2009 ).
Josef Vanek and Otto Jírovec had shown the direct correlation between the presence of P. jiroveci and human disease of preterm infants with interstitial plasma cell pneumonia in 1951 (Vanek & Jírovec 1952) . The PcP almost disappeared, when social and health conditions for infants were improved. Interest in PcP was renewed with the advent of AIDS, and knowledge about PcP as the most common opportunistic diseases in persons with positive HIV antibody. Pulmonary complications are very common in immunocompromised patients, and delayed initiation of appropriate therapy increases the risk of patient's death. Airborne transmission of P. jiroveci has been demonstrated in animal models and is highly probable in humans. Human pneumocystosis is anthroponotic. Healthy adults represent a dynamic reservoir and source of infection for human Pneumocystis species. P. jiroveci DNA was detected in the upper respiratory tract of healthy participants after close contact with patients with PcP and in air samples from the rooms of PcP patients. P. jiroveci has also been found in immunosuppressed patients without PcP; these situations have been described as pneumocystis colonization or carriage (Medrano et al. 2005 ). The infection is localized mostly in the lung tissue and, more rarely, in extrapulmonary locations (cervical and tracheal lymph nodes, spleen, thymus, lumens of blood vessels, liver, bone marrow, adrenals, brain, kidneys, gastrointestinal tract, heart, liver, thyroid, pericardium, and hard palate, ears, eyes) primarily in severely immunocompromised hosts (Anuradha & Sinha 2007) . The classic symptoms of patients with PcP are dry, nonproductive cough, fever, weight loss, and shortness of breath (Jang-Jih & Chao-Hung 2008) . The first choice of drug for treatment is trimethoprimsulfamethoxazole. The second choice is a combination of primaquine and clindamycin for those who are allergic to sulfa. Pentamidine, atovaquone, and combination of dapsone and trimethoprim are alternative choices (Kovacs et al. 2001) . Echinocandins are new antifungals effective against P. jiroveci that target a glucan synthesis in fungi. The therapeutic effects of anidulafungin, caspofungin and micafungin were more effective against cyst form. It was due to the presence of glucan in the cyst form, while glucan is nonexistent or at very low levels in the trophic form (Cushion & Collins 2011) .
The current laboratory diagnosis of PcP is usually achieved by demonstrating the presence of P. jiroveci in induced sputum or bronchoalveolar lavage (BAL) fluid. The most commonly cytochemical staining methods used in microscopy are Giemsa, Gram-Weigert stain, Grocott-Gomori methenamine silver, toluidine blue, calcofluor (nonspecific fluorescence) and merifluor (specific fluorescence). Diagnostic of PcP may be more difficult in AIDS patients who used aerosolized pentamidine for prophylaxis. Inhaled pentamidine significantly reduces the number of P. jiroveci. The lack of robust, long term culture has prevented detailed knowledge about pneumocystis organisms (Aliouat-Denis et al. 2009 ). Tests for antibody to P. jiroveci are not helpful for diagnosis, because most healthy individuals have antibody that can be detected by methods (ELISA, CFT) currently in use. These tests can be used in epidemiological screening. Polymerase chain reaction (PCR) technology was first applied to the diagnosis of PcP by Wakefield et al. (1990) . The targets of this method include dihydropteroate synthase, dihydrofolate reductase, thymidylate synthase, β-tubulin, cdc2 gene, mitochondrial large subunit rRNA, and mitochondrial small subunit rRNA. The most commonly used primers are pAZ102-E and pAZ102-H amplified part of the mitochondrial large subunit rDNA (Wakefield et al. 1990 ). Radiographic and CT equipment are used in clinical practice for the diagnosis of PcP.
Material and methods
During the 10 year study period we examined 386 patients suspected of PcP infection. All patients were investigated for pulmonary symptoms characterized by dyspnea, cough, and fever and abnormal chest radiographs. Three hundred sixteen BAL, 59 induced sputum, 10 lung biopsies and 1 liquor were collected from 231 men and 155 women. The majority of patients were treated on departments of oncology and respiratory diseases, situated in the Bratislava region.
Specimen processing: Sputum samples had to be homogenized by the use of dithiothreitol (0.1%). Clinical specimens were centrifuged at 1500× g for 10 min. (Chichino et al. 1990) . A portion of the pellet was smeared on slides and Giemsa and Gram-Weigert stained for microscopic evaluation. The second part of the pellet was kept frozen at -20
• C until DNA was extracted. All the samples were subjected to microscopic examination and PCR assay.
Giemsa staining: Trophic and cystic forms of P. jiroveci can be detected. Samples were fixed with absolute methanol, air-dried and stained with a 5% Giemsa solution for 30 min. (Giemsa 1904) .
Gram-Weigert staining: Cysts of P. jiroveci can be identified by Gram-Weigert staining. Samples were fixed with absolute methanol, air-dried and stained for 5 min. with 1% eosin Y, solution of crystal violet, Gram's iodine solution, respectively. For differentiation we used a solution of aniline-xylene and xylene (Garcia & Bruckner 1997) .
DNA isolation: The DNA from BAL, sputum, lung biopsies and liquor was extracted by using a PathogenFree DNA Isolation Kit (GeneProof, Czech Republic) according to the manufacturer's recommendations.
PCR amplification: For P. jiroveci, clinical samples were further analysed using conventional PCR assay targeting the mitochondrial large subunit rDNA with primers pAZ102-E and pAZ102-H, and the expected fragment length of 345 bp (Tamburrini et al. 1993) . The initial denaturation step consisted of heating the reaction to 94
• C for 120 s. Thirty cycles consisting of denaturation at 94
• C for 30 s, annealing at 53
• C for 30 s, and extension at 72
• C for 30 s were performed. Thereafter, a final extension for 5 min. at 72
• C was done. PCR products were investigated by agarose gel electrophoresis (1.5%), stained with ethidium bromide, and illuminated under UV light. Positive controls (DNA extracted from a BAL which was strongly positive based on the microscopic analysis) and negative controls (autoclaved water and the PCR mixture minus the DNA template) were included in each PCR assay. The detection limit of this PCR assay was 1 organism/µl of extracted DNA. To prevent falsepositives from contamination, pipettes with filters were used in all manipulations. DNA extraction, preparation of the reaction mixture, PCR amplification, and detection were performed in different areas under a laminar flow hood. To detect any cross-contamination, all PCRs were performed with negative controls. For PCR-positive samples with negative conventional-staining results (PCR-positive samples were reexamined microscopically by two different persons) DNA isolation was repeated and an additional PCR was performed. A positive result was accepted when this PCR determination was also positive.
Statistical analysis: Analysis of 2 × 2 tables was undertaken using the MedCalc diagnostic test evaluations program version 11.6.1, for Windows (MedCalc Software; http://www.medcalc.org/calc/diagnostic test.php). (Fig. 1) .
Results

Diagnosis of P. jiroveci in patients during
Pneumocystis jiroveci was identified by PCR in 30 samples and in 4 of them microscopically as well. P. jiroveci was detected in 24 BAL samples and 6 sputum collected from patients. The presence of P. jiroveci was confirmed especially in immunocompromised persons with cancer (20), but also in patients with pneumonia (6+1 HIV), with unspecified parasitic diseases (1+1 HIV) and with systemic lupus erythematosus (1). Pneumocystis infection in 6 patients with cancer had to be checked by subsequent repeated tests. Number of repeated studies ranged from 2 to 7. In 2 patients, P. jiroveci was detected from the third and fourth sample. Patients with malignancies included 7 non-Hodgkin's lymphomas, 6 lymphocytic leukemias, 3 Hodgkin's diseases, 1 myelogenous leukemias, 1 malignant brain tumor, 1 renal malignancy and 1 malignancy of connective and other soft tissue. The large number of these patients exhibited symptoms such as coughing, trouble breathing, chest pain, shortness of breath. They had swollen and painless lymph nodes, frequent infections accompanied by fever. Unexplained weight loss, night sweats and weakness were also present. The second large group within our PCR positive cohorts consisted of patients with respiratory diseases such as 4 pneumonia caused by unspecified microorganisms, 1 acute bronchitis, 1 bacterial pneumonia, 1 pneumonia in diseases classified elsewhere and 1 respiratory failure. The main clinical signs for these patients were a non-productive cough (because sputum was too viscous to become productive), shortness of breath (especially on exertion) and fever. Lesser significant symptoms included production of sputum, blood in sputum, chest pain and difficulty breathing.
Microscopic evidence
According to the results of the Giemsa-and GramWeigert-stained clinical specimens, cysts of P. jiroveci were identified in 4 cases by microscopy. In this study, we did not identify the presence of trophozoites. Figure 2 shows one of the positive specimens staining by the Gram-Weigert. The cysts have an irregular morphology, deformed shape of the ball, and their sizes vary from 4 to 8 µm in diameter. The wall of pneumocystis cysts was selectively stained by the Gram-Weigert, it was purple or blue, and other material (eosinophils, alveolar cells, pneumocytes) pink or purple.
PCR
Three hundred eighty-six clinical samples from patients with various diagnoses were prospectively examined by PCR. In 30 (7.8%) cases (16 males and 14 females), was detected P. jiroveci amplifying the part of the mi- tochondrial large subunit rDNA. Induced sputum was positive in 6 of the 59 sputum samples, providing a yield of 10.2%. BAL was positive in 24 of the 316 BAL samples, i.e. a yield of 7.6%.
Sensitivity and specificity of selected methods used for diagnosis of P. jiroveci We have expressed sensitivity and specificity of microscopic evidence with regard to the PCR, which was considered as the gold standard. On the basis of a binary classification test were calculated these statistical measures of the diagnostic accuracy of laboratory tests. Compared with the PCR, sensitivity, specificity, positive predicted value and negative predicted value for microscopy were 18.2%, 100%, 100% and 93.3%, respectively.
Discussion
Our study provides an overview of the P. jiroveci presence in patients with pulmonary complications, which has not yet been presented to this time in Slovakia. The data in this paper indicate the possibility of laboratory diagnosis in routine laboratory conditions. Several authors have compared the sensitivity of PCR with other staining methods for PcP diagnosis. The majority of published studies have reported significantly higher sensitivity rates for PCR than for conventional cytological colouring techniques when BALs, induced and non-induced sputum are examined material. Wakefield et al. (1990) achieved 90% sensitivity of PCR in comparison with 35% sensitivity of microscopy. The PCR of BAL and induced sputum specimens from patients was 100% sensitivity described by Chouaid et al. (1995) . The results of epidemiological study performed by Golab et al. (2011) indicated that in differential diagnosis of P. jiroveci infections in children molecular methods are useful as their high sensitivity makes it possible to analyse non-invasive samples. On the contrary, some authors have questioned the benefits of using PCR for the diagnosis of P. jiroveci in induced sputum compared with microscopy and evaluated the PCR as an expensive, time consuming and unsuitable method for rapid detection of PcP (Armbruster et al. 1995) . Liebovitz et al. (1995) assessed the PCR and staining techniques such as comparative methods for BAL investigation. Because we did not have the clinical picture and anamnesis of all investigated patients and whether the person actually had a disease corresponding to PcP, we considered PCR results as the gold standard. We found a significantly lower sensitivity of microscopic evidence in comparison with PCR method, similar to most published research papers. Microscopic test (staining by the Gram-Weigert) is rapid, relatively inexpensive, but requires professional experience in the evaluation of results. Consequently, microscopy is a suitable screening test to detect P. jiroveci, but PCR is more sensitive. By microscopy, 81.8% of samples were false negative, and this method was able to detect only cystic stages. Trophic forms are the most abundant of all pneumocystis life cycle stages, representing 90-95% of the total population in the lungs of hosts with pneumocystosis (Cornillot et al. 2002) . For this reason, microscopic evidence may fail to detect trophozoites and confirms that the evidence of pneumocystis DNA by PCR is a reliable method for detecting P. jiroveci in our laboratory. On the other side, PCR method could produce a significant percentage of falsepositive results while microscopy could correctly identify all clinically confirmed PcP cases without yielding a false-positive result like in the study of Sing et al. (2000) . Morris et al. (2004) reported that P. jiroveci DNA in human clinical samples from persons who did not have signs or symptoms of infections and who did not progress to infection had been defined as colonization or subclinical carriage. They detected pneumocystis DNA only by PCR, and the organism was not seen on routine histochemical staining. The clinical significance of P. jiroveci in respiratory specimens and viability of organisms detected only by PCR were unknown. In the study of Reid et al. (2011) , conventional PCR increased diagnostic sensitivity but may have detected asymptomatic colonization. They claimed that quantitative PCR demonstrated potential for distinguishing colonization from infection, but clinical validation was required. In the entire population, we detected P. jiroveci especially in people with cancer (5.2%), subsequently in patients with pneumonia (1.8%), with un-specified parasitic diseases (0.5%), HIV (0.5%) and finally with systemic lupus erythematosus (0.3%). Sing et al. (2000) diagnosed PcP in HIV (6%), following cancer (1.8%) and transplanted patients (1.5%), respectively. In our group of persons under investigation (386), the number of patients with HIV infection (2) was not so high in comparison with 89 HIV-positive patients out of 334 examined cases presented by Sing et al. The majority of P. jiroveci-positive patients were immunosuppressed (76.7%) like in the study of Sing et al. (94.3%) .
In view of the increasing number of immunocompromised persons, diagnostics of P. jiroveci in patients with pulmonary complications is essential. Our study also confirmed the previously reported claim, the number of examinations and detection of opportunistic pathogen has grown during the last 10 years. We were able to detect the causal agents responsible for serious pulmonary complications in 30 (7.8%) immunocompromised patients.
